ALB and glioblastoma: The findings of this first attempt investigating the prognostic utility of CRP/Alb in newly diagnosed GBM patients treated with RT plus concurrent and adjuvant TMZ revealed that a pretreatment CRP/Alb ≥0.75 was strongly related to poorer survival outcomes.